GLAXOSMITHKLINE PLC 13D and 13G filings for Spero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-28 4:30 pm Unchanged |
2025-03-27 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 9,190,606 16.400% |
0 (Unchanged) |
Filing |
| 2023-01-20 4:08 pm Unchanged |
2022-11-14 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 9,190,606 17.750% |
0 (Unchanged) |
Filing |
| 2022-11-14 5:02 pm Purchase |
2022-11-07 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 9,190,606 19.990% |
7,450,000 (+428.01%) |
Filing |
| 2021-09-16 5:27 pm Unchanged |
2021-08-05 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 1,740,606 5.400% |
0 (Unchanged) |
Filing |
| 2020-12-07 5:08 pm Sale |
2020-11-05 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 1,740,606 6.400% |
-78,872 (-4.33%) |
Filing |
| 2020-06-04 5:03 pm Sale |
2020-06-01 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 1,819,478 8.800% |
-114,528 (-5.92%) |
Filing |